Kuda Therapeutics is a Salt Lake City based oncology company focused on the development of first-in-class therapeutics for cancer. Kuda is funded entirely by non-dilutive government grants and retains full ownership of intellectual property rights to its lead product, KD061. KD061 is an orally available small molecule which induces cell death through ferroptosis with significant ~70% anti-tumor activity in mouse models of cancer. KD061 has a secondary on-target effect in blocking the hypoxia-inducible factors (HIFs) which contributes to its anti-tumor efficacy. Kuda’s focus is to complete the non-clinical and toxicological studies needed to support an Investigational New Drug (IND) filing on its lead product, KD061. To date, the Company has been awarded ~$3.4M in government research grants and is now seeking $2.5M from private investors to fund the remaining costs associated with the IND filing activity.